Abstract
The phenomenal success and worldwide acceptance of mRNA vaccines against COVID-19 has highlighted one remarkable aspect of these vaccines — the ease of scale-up and the fast manufacturing of the vaccines. The timeline from starting the development (by making the plasmid DNA construct for the spike protein) to FDA Emergency Use authorization was accomplished in less than two years. The reasons for this “Warp Speed” accomplishment are varied, and we will go through each step to highlight where translation was rapid.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: World Scientific Annual Review of Functional Materials
Paper Title
Journal
Date
